嵌合抗原受体 T 细胞疗法的最新进展。
Recent Advances in CAR-T Therapy.
机构信息
University of Maryland Medical Center, Baltimore, MD, USA.
出版信息
Cancer Control. 2024 Jan-Dec;31:10732748241263713. doi: 10.1177/10732748241263713.
Abstract
Chimeric antigen receptor T cell therapy is used to treat hematological malignancies which are refractory to standard therapy. It is a form of immunotherapy in which a patient's T cells are programmed to act against tumor cells. We discuss the process of manufacturing CAR-T cells, the common side effects of therapy, and the recent emerging risk of T-cell malignancies after treatment.
摘要
嵌合抗原受体 T 细胞疗法用于治疗对标准疗法耐药的血液系统恶性肿瘤。它是一种免疫疗法，通过该疗法可以对患者的 T 细胞进行编程，使其针对肿瘤细胞发挥作用。我们讨论了制造 CAR-T 细胞的过程、治疗的常见副作用以及治疗后 T 细胞恶性肿瘤最近出现的新风险。
相似文献
1
Recent Advances in CAR-T Therapy.
Cancer Control. 2024 Jan-Dec;31:10732748241263713. doi: 10.1177/10732748241263713.
2
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14.
3
Advances in CAR-T-cell therapy in T-cell malignancies.
J Hematol Oncol. 2024 Jun 24;17(1):49. doi: 10.1186/s13045-024-01568-z.
4
CAR T-cell therapy: perceived need versus actual evidence.
Lancet Oncol. 2018 Oct;19(10):1259. doi: 10.1016/S1470-2045(18)30698-3. Epub 2018 Oct 1.
5
Adoptive therapy with CAR redirected T cells for hematological malignancies.
Sci China Life Sci. 2016 Apr;59(4):370-8. doi: 10.1007/s11427-016-5036-3. Epub 2016 Mar 22.
6
Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Clin Pharmacol Ther. 2019 Jan;105(1):71-78. doi: 10.1002/cpt.1280.
7
How can we improve the successful identification of patients suitable for CAR-T cell therapy?
Expert Rev Mol Diagn. 2024 Sep;24(9):777-792. doi: 10.1080/14737159.2024.2399152. Epub 2024 Sep 11.
8
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3.
9
Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
J Hematol Oncol. 2019 Dec 29;12(1):141. doi: 10.1186/s13045-019-0801-y.
10
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021.
引用本文的文献
1
Tandem CAR-T cell therapy: recent advances and current challenges.
Front Immunol. 2025 Feb 28;16:1546172. doi: 10.3389/fimmu.2025.1546172. eCollection 2025.
本文引用的文献
1
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
J Transl Med. 2023 Jul 7;21(1):449. doi: 10.1186/s12967-023-04292-3.
2
CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Curr Hematol Malig Rep. 2023 Apr;18(2):9-18. doi: 10.1007/s11899-023-00687-7. Epub 2023 Feb 10.
3
CAR T-cell therapy for B-cell lymphoma.
Curr Probl Cancer. 2022 Feb;46(1):100826. doi: 10.1016/j.currproblcancer.2021.100826. Epub 2021 Dec 25.
4
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.
5
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
6
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.
7
The basic principles of chimeric antigen receptor design.
Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2.
Zotero 插件